Supplemental Material: Real-world efficacy of ritlecitinib in treating alopecia areata across various anatomical sites: Potential rapid response predictors

This real-world study aimed to evaluate the effectiveness and safety of ritlecitinib in a heterogeneous cohort of AA patients and identify response in scalp as well as lashes, brows and nails, and clinical predictors of early treatment response.We conducted a single-center retrospective cohort study of consecutive patients receiving ritlecitinib 50 mg daily for ≥12 weeks. Disease severity was assessed at baseline and weeks 4, 8, 12, 24, and 36. Treatment-emergent adverse events (AEs) were systematically recorded. Multivariate logistic regression models assessed the link between treatment response and clinical predictors.